GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ligufalimab   Click here for help

GtoPdb Ligand ID: 13887

Synonyms: AK-117 | AK117
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ligufalimab (AK117) is a humanized IgG4 anti-CD47 antibody [1-2]. In the tumour microenvironment blocking CD47 interaction with its receptor SIRPα enhances M2 macrophage-mediated phagocytosis of CD47-expressing malignant cells from variety of tumour types. Unlike other anti-CD47 antibodies (such as magrolimab) ligufalimab does not induce hemagglutination, so should be devoid of hematotoxic side effects (anemia and thrombocytopenia) due to the expression of CD47 on erythrocytes.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
Ligufalimab disrupts the CD47-SIRPα anti-phagocytic checkpoint, which induces an immunostimulating effect that promotes macrophage-mediated phagocytosis of tumour cells.